



Docket No.: 223002010004
(APPLICATION)

IN THE UNITED STATES APPLICATION AND TRADEMARK OFFICE

In re Patent Application of:
Michael HOUGHTON et al.

Application No.: 09/884,455

Art Unit: 1656

Filed: June 18, 2001

Examiner: W. Moore

For: HEPATITIS C VIRUS PROTEASE

SECOND DECLARATION OF AMY J. WEINER
UNDER 37 C.F.R. § 1.132

I, Amy J. Weiner, declare and affirm that:

1. I am currently Director of Research, Vaccines and Antivirals at Novartis Corporation (formerly Chiron Corporation), Emeryville, California.
2. I have a Ph.D. in Molecular, Cellular and Development Biology from Indiana University. Since 1984 I have been involved in research on hepatitis viruses.
3. I am not an inventor of U.S. Application No. 09/884,455.
4. I have read the above referenced U.S. Application No. 09/884,455, and I understand the subject matter contained therein. I am qualified to comment on what one of ordinary skill in the art would understand from reviewing the disclosure of this application and the publications referred to in my declaration.
5. I have previously submitted a declaration in the prosecution of this application.

A. U.S. Application No. 09/884,455 discloses a HCV protease

6. I have reviewed U.S. Application No. 09/884,455 ("the '455 application") and believe that one of skill in the art would understand that the specification discloses a Hepatitis C Virus (HCV) protease.

7. The application specification states that: "[t]he term 'HCV protease' refers to an enzyme derived from HCV which exhibits proteolytic activity, specifically the polypeptide encoded in the NS3 domain of the HCV genome." (page 6, lines 22-24)

8. An HCV NS3 domain protease sequence is provided in Figure 1 of the application specification. (page 3, line 7).

9. An HCV protease encoded by the NS3 domain in at least one strain of HCV is further described with reference to a 202 amino acid protease sequence from SEQ ID NO: 1 in page 6, line 26 to page 7, line 18 (SEQ ID NO: 65).

B. U.S. Application No. 09/884,455 discloses a HCV NS3 domain serine protease

10. The specification describes an NS3 domain of HCV. Page 5, line 11 to page 6, line 4 refer to NS3 domain by analogy with the Yellow Fever Virus (a flavivirus) polyprotein. The specification points to a specific section in the NS3 domain as the key to proteolytic activity. (page 7, line 19 through page 8, line 6).

11. Pages 8-9 identify active residues responsible for protease activity by alignment with related serine protease sequences. Table 1 of the '455 application discloses HCV peptides from within SEQ ID NO: 65 and by alignment with catalytic residues of flavivirus serine proteases, identifies His-1083, Asp-1107 and Ser-1165 of the HCV genome as active residues for serine protease activity. Table 2 confirms the identification of the same residues by structural alignment with well-characterized serine proteases.

12. Examples 10 and 11 (pages 37- 39) provide methods for expression *in vitro* of HCV protease as a method for confirming the disclosure of HCV NS3 serine protease.

13. Eckart *et al.* (Biochem. Biophys. Res. Commun. 192:399-406 (1993).) used an *in vitro* transcription translation system to demonstrate a protease activity encoded by the NS3 domain that was mediated by the Ser-1165 residue identified in Table 1 of the specification.

(i) NS3 serine protease cleaves several substrates in the absence of the cofactor NS4A

14. It is now known that the NS3 serine protease cleaves the HCV polyprotein at multiple sites – NS3/4A, NS4A/4B, NS4B/5A and NS5A/5B. Only the NS4B/5A cleavage is dependent on the presence of NS4A. Bartenschlager *et al.* (J Virol. 68(8):5045-5055 (1994)).

Bartenschlager has also shown that the first 211 amino acids of NS3 were sufficient for processing at all *trans* sites.

15. The NS3 serine protease mediated cleavages at NS3/4A, NS4A/4B and NS5A/5B are processed efficiently in *trans* by the NS3 serine protease without NS4A as follows:

By using an NS3-5B substrate with an inactivated serine proteinase domain, trans-cleavage was observed at all sites except for the 3/4A site. Deletion of the inactive proteinase domain led to efficient trans-processing at the 3/4A site. Smaller NS4A-4B and NS5A-5B substrates were processed efficiently in trans; however, cleavage of an NS4B-5A substrate occurred only when the serine proteinase domain was coexpressed with NS4A.

Abstract, Lin *et al.*, J. Virol. 68(12): 8147-8157 (1994).

16. I have reviewed Sardana *et al.* (Protein Expression and Purification 16:440-447 (1999)). I understand Sardana to show that the NS4A cofactor is essential for "high" proteolytic activity of the NS3 serine protease. (*see* Abstract). Sardana acknowledges that proteolysis at the NS4A/4B junction is carried out at detectable levels by the NS3 serine protease in the absence of NS4A. (Sardana at 443, left col.).

17. Vishnuvardhan *et al.* (FEBS Lett. 402(2-3):209-212 (1997)) shows that a NS3 serine protease representing amino acids 1027–1218 of the HCV polyprotein, and not including any NS4A region, cleaves the NS5A/5B junction in the absence of NS4A. (Figs. 1 and 3). NS4A (amino acids 1658-1712; *see* Fig. 1) enhances the cleavage but is not essential for it. (Fig. 3).

Further, Vishnuvardhan classifies the NS4A/4B cleavage site as "NS4A-independent" cleavage site. (at 211).

18. Barbato *et al.* J. Mol. Biol. (1999) 289, 371-384, at 382, left col. states that "[i]nteraction with the NS4A cofactor is required to perform the cleavages at NS3/NS4A, NS4A/NS4B and NS4B/NS5A junctions but the proteinase in its uncomplexed state is still able to cleave at the NS5A/NS5B boundaries, although with a much lower activity."

19. The functionally minimal domain required for activity of the NS3 serine protease is composed of 146 amino acids, 1059 to 1204. (Yamada *et al.* Virology 246: 104-112 (1998)).

20. Figure 1 and SEQ ID NO.1 (page 6-7) of the '455 application discloses a sequence that encompasses the entire minimal domain of the NS3 serine protease.

21. The NS3 minimum domain can function as a protease from a structural point of view. Love *et al.* Cell 87: 331-342 (1996).

(ii) Polyprotein substrates for NS3 serine protease activity are disclosed in the Specification, and viral polyprotein substrates for proteases were commonly used in the art

22. Protease assays using *trans*-cleavage of viral polyprotein substrates were known in the art at the time of the filing of the invention. The following examples show the widespread use of viral polyproteins as substrates for viral proteases prior to 1988.

- Processing of a 250 kDa Sindbis Virus polyprotein substrate (S1234) *in vitro* by Sindbis Virus protease prepared by *in vitro* translation. de Groot, *et al.* The EMBO J. 9(8)2631-2638 (1990):
- *Trans* cleavage of a poliovirus capsomer precursor protein by poliovirus Proteinase 3C. Nicklin: J. Virol (1988) 62: 4586-4593.
- *Trans* assay of MLV protease using Gazdar murine sarcoma virus (Gz-MSV) polyprotein Pr65(gag) substrate. Yoshinaka, Proc Natl Acad Sci U S A. (1985) 82(6):1618-1622.

- *Trans* assay of FeLV protease using Gazdar murine sarcoma virus (Gz-MSV) polyprotein Pr65(gag) substrate. Yoshinaka, J. Virol. (1985) 55(3):870-873.
- *Trans* assay of BLV protease using MLV polyprotein Pr65(gag) substrate. Yoshinaka *et al.*, J. Virol. (1986) 57(3):826-832.
- The proteinase of human immunodeficiency virus (HIV), expressed in Escherichia coli, shows rapid, efficient, and specific cleavage of an *in vitro* synthesized gag precursor polyprotein. Kräusslich *et al.*, Proc Natl Acad Sci U S A. (1989) 86(3): 807–811.
- Processing of HIV-1 Pr53(gag) polyprotein substrate in *trans* (Fig. 4) by hSOD-HIV2 protease fusion from bacteria and yeast. Pichuanes *et al.* J. Biol. Chem 265(23):13890-13898 (1990)
- A fusion protein comprising HIV1 protease fused with human superoxide dismutase (hSOD) expressed in yeast displayed correct self-processing, and *trans*-processing *in vitro* of a gag-precursor Pr53^{gag} polyprotein substrate. (see Fig. 4, Table 1, Pichuanes *et al.*, Proteins. 6:324-37 (1989))

23. A substrate for the serine protease activity in the form of genomic HCV polyprotein is disclosed in page 20, lines 14-16 of the specification. Page 21, lines 4-5 explains that "[i]n the absence of this protease activity, the HCV polyprotein should remain in its unprocessed form."

24. A method for inactivating the HCV protease activity by a single point mutation "substituting Ala for Ser₁₂₁" is disclosed in page 22, line 27 to page 23, line 15 of the specification. One of skill in the art would have understood that this method can be used to inactivate the NS3 serine protease activity of the genomic HCV polyprotein – such that it can then be used as a substrate for testing NS3 serine protease activity in *trans*.

25. Lin *et al.* used such a substrate with an inactivated serine proteinase domain to assay trans-cleavage by NS3 serine protease. (Lin *et al.*, J. Virol. 68(12): 8147-8157 (1994))

26. One of skill in the art would understand that the '455 application describes a NS3 serine protease based on comparison with related flavivirus proteases and identification of critical amino acid residues of the serine triad. One of skill in the art would also understand that a substrate for the NS3 serine protease activity in the absence of NS4A cofactor is disclosed in the '455 application in the form of genomic HCV polyprotein.

C. An NS2/3 protease activity associated with the HCV NS3 domain is disclosed in the Specification.

27. Example 5 of the Specification of the '455 application discloses specific NS2/3 cleavage by hSOD-NS3 domain fusion polypeptides as discussed in detail in my first declaration on paragraphs 7-14.

(i) The 34 kDa protein shown in Example 5 of the Specification corresponds to self-cleavage product of the NS2/3 protease fusion protein

28. A 34 kDa band corresponding to a product of specific self-cleavage comprising hSOD and part of the NS3 domain comprising residue 946 to the NS2/3 cleavage site is consistently observed with fusion proteins P300, P500 and P600, but not with P190 which lacks the activity of NS2/3 protease.

29. Determination of exact molecular weight by SDS-polyacrylamide gel electrophoresis can be unpredictable. It is now known that the specific NS2/3 self cleavage product comprises 151 amino acids of hSOD and amino acids 1-82 shown in Figure 1. The theoretical size of this fragment without any post translational processing would be expected to be about 25 kDa. However, in Example 5, the 34 kDa size is estimated from a Western blot of a SDS-polyacrylamide gel.

30. While SDS-polyacrylamide gel electrophoresis is often used to estimate molecular weights of proteins by comparing migration of proteins relative to a set of standard markers, it is well-known in 1991 that proteins and proteases do not necessarily migrate on SDS-polyacrylamide gels according to their predicted molecular weight.

- "[A]bnormalities in SDS binding or protein conformation, large differences in intrinsic protein charge, ... may lead to increased or decreased electrophoretic mobilities; therefore caution is advisable in use of this technique." *Proteins: Structural and Molecular Principles*. T. Creighton. page 33. (WH Freeman and Co., New York, © 1984).
- "[D]iscrepancy between apparent relative masses and real molecular weights underlies the uncertainty in deducing molecular masses of membrane-bound proteins from their mobility in electrophoretic gels." *Introduction to Protein Structure*. Brande C., and Tooze J. page 204 (Garland Publishing, Inc. New York and London © 1991).

31. Several proteases are known to migrate according to anomalous molecular weights in SDS-polyacrylamide gel electrophoresis:

- A NS2B-NS3 fusion protein from Dengue virus – a member of the flavivirus family which includes HCV – with a predicted molecular weight of 29.8 kDa displays anomalous migration in SDS-polyacrylamide gel electrophoresis with a higher apparent molecular mass of 37 kDa. Niyomrattanakit P., et al. *J. Virol.* (2004) 78(24): 13708-13716, at 13711, left column.
- A serine protease with a predicted molecular weight of 24.205 kDa was found to migrate at greater than 26 kDa possibly due to "the presence of bound [protein] defensin, possible posttranslational modifications of the protease, incomplete reduction of the protease during sample preparation or any combination of these possibilities." Hamilton JV et al., *Insect Molecular Biology* (2002) 11(3): 197–205, at 204, left column.

32. The specification shows that estimates of molecular weights of known proteins from SDS-polyacrylamide gel electrophoresis were not precisely according to the predicted theoretical size. For example, the molecular weight of the 151 amino acid hSOD partner by itself was estimated by gel electrophoresis to be about 20 kDa on page 31, lines 15-16, whereas its theoretical size is 16.5 kDa.

33. From the consistent observation of a 34 kDa band reactive to anti-HCV antisera described in Example 5 of the specification of the '455 application, corresponding to the active fusion proteins P300, P500 and P600, but not with the inactive P190 fusion, one of skill in the art would have understood the "34 kDa" band to correspond to the product of specific cleavage by the NS2/3 protease.

(ii) Stable and active viral protease fusion proteins were known in the art prior to 1991

34. It is known that fusion of heterologous sequences to the N-terminus of proteases does not affect the proteolytic activity of the protease. Human Immunodeficiency Virus (HIV) proteases remain active when a heterologous sequence is added to either terminus. The fused proteases mediate self-cleavage of viral polyproteins at the correct cleavage sites.

- A fusion protein comprising sequences from chloramphenicol acetyltransferase enzyme and HIV-1 protease is capable of autoprocessing, and mutation of the active site residue results in incorrect cleavage. Montgomery *et al.*, Biochem. Biophys. Res. Comm., 175(3):784-94 (1991).
- An HIV protease fused to the amino or carboxy terminus of bacterial β -galactosidase retains its capacity for specific autoprocessing. Valverde *et al.*, J. Gen. Vir. 73:639-51 (1992)

35. As of the filing date of the parent application, April 4, 1991, fusion of a protein of interest to human superoxide dismutase (hSOD) sequence was an established method of achieving high-level expression of a stable fusion protein. The specification of the '455 application discloses expression of HIV protease as a fusion with human superoxide dismutase (hSOD) and having autocatalytic proteolysis activity by Pichuanes *et al.*

36. Prior to 1991, examples of HIV proteases fused with hSOD and showing proteolytic activity for self-cleavage as well as cleavage using viral polyprotein substrates in *trans*, had been observed:

- hSOD-HIV2 protease fusion from bacteria and yeast correctly processes HIV-1 Pr53(gag) polyprotein in trans (Fig. 4). Pichuantes *et al.* J. Biol. Chem 265(23):13890-13898 (1990)
- A fusion protein of HIV1 protease with human superoxide dismutase (hSOD) expressed in yeast displayed correct self-processing, and *trans*-processing of gag-precursor Pr53^{gag} substrate in *in vitro* assays (*see* Fig. 4, Table 1, Pichuantes *et al.*, Proteins. 6:324-37 (1989))

(iii) From a review of the specification, one of skill in the art would understand that fusion of heterologous hSOD polypeptide sequence to a truncated NS2/3 protein, that by itself is inactive, restored activity of the NS2/3 protease activity.

37. It has been observed that fusion of a heterologous polypeptide sequence to a truncated fragment of a protein that by itself is inactive, can restore activity of the protein fragment. A fragment containing the first domain of the CD45 protein lacks phosphatase activity, but fusion of this fragment to maltose-binding protein restores the phosphatase activity. Lorenzo *et al.*, FEBS. 411(2-3):231-5 (1997).


38. Fusion with hSOD had been observed to stabilize the HIV protease. (*see* Pichuantes *et al.* J. Biol. Chem 265(23), at p.13892, col. 2 (1990))

39. The fusion of the NS2/3 fragments containing 299, 513 or 686 residues downstream from residue 946 to the 151 amino acids long hSOD fragment displayed NS2/3 specific protease activity, as shown in Example 5.

40. One of skill in the art would understand from Example 5 in the specification, that fusion of the heterologous hSOD sequence to the NS2/3 fragments containing the 299, 513 or 686 residues, was sufficient to restore NS2/3 specific protease activity.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the above-identified application or any application issuing thereon.

Executed this 6th day of February, 2007



Amy J. Weiner, Ph.D.